Researchers Find Link Between Graft-Versus-Host Disease and Sexual Dysfunction

A common and serious condition affecting some patients following a stem cell transplant may also be leading to sexual dysfunction.

Researchers from the City of Hope Cancer Research Hospital in Duarte, Calif., where many stem cell transplants are done annually, are reporting in the journal Blood that graft-versus-host disease (GVHD) – the complication following a transplant in which the graft (stem cells) begin attacking the host – is a possible cause of sexual dysfunction and diminished sexual health in these patients.

The study

Investigators identified 277 adults (152 men and 125 women) who had a stem cell transplant between 2001 and 2005 at City of Hope and asked them to complete three questionnaires five separate times: 17 days before the SCT procedure, and six, 12, 24 and 36 months after the procedure.

Two of the questionnaires concerned sexual function, namely with questions about sexual cognition, sexual arousal, sexual behavior/experience, orgasm and sex drive/relationship, while the third concerned quality of life.

Decline in sexual satisfaction

In those patients who had chronic GVHD, there was a 21 percent decline in sexual cognition/fantasy in men and a 24 percent decline in the quality of orgasm. Women with chronic GVHD reported a 27 percent decline in sexual satisfaction and the same decline percentage in sexual arousal.

In sum, investigators determined that almost half of survivors in the study were sexually inactive within three years of the procedure.

"It is not often that the transplant team and patient will have a conversation about how this procedure could impact their sex life, even after recovery," said lead author Dr. Lennie Wong. "However, we hope these findings will help encourage patients and their doctors to openly discuss concerns related to sexual dysfunction and address them with specialists who can help."

Source: MNT

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap